The Transmembrane Adaptor Protein SIT Inhibits TCR-Mediated Signaling by Arndt, Börge et al.
The Transmembrane Adaptor Protein SIT Inhibits TCR-
Mediated Signaling
Bo ¨rge Arndt
1¤, Tina Krieger
1, Thomas Kalinski
2, Anja Thielitz
3, Dirk Reinhold
1, Albert Roessner
2,
Burkhart Schraven
1, Luca Simeoni
1*
1Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany, 2Institute of Pathology, Otto-von-Guericke University
Magdeburg, Magdeburg, Germany, 3Clinic of Dermatology and Venerology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
Abstract
Transmembrane adaptor proteins (TRAPs) organize signaling complexes at the plasma membrane, and thus function as
critical linkers and integrators of signaling cascades downstream of antigen receptors. We have previously shown that the
transmembrane adaptor protein SIT regulates the threshold for thymocyte selection. Moreover, T cells from SIT-deficient
mice are hyperresponsive to CD3 stimulation and undergo enhanced lymphopenia-induced homeostatic proliferation, thus
indicating that SIT inhibits TCR-mediated signaling. Here, we have further addressed how SIT regulates signaling cascades in
T cells. We demonstrate that the loss of SIT enhances TCR-mediated Akt activation and increased phosphorylation/
inactivation of Foxo1, a transcription factor of the Forkhead family that inhibits cell cycle progression and regulates T-cell
homeostasis. We have also shown that CD4
+ T cells from SIT-deficient mice display increased CD69 and CD40L expression
indicating an altered activation status. Additional biochemical analyses further revealed that suppression of SIT expression
by RNAi in human T cells resulted in an enhanced proximal TCR signaling. In summary, the data identify SIT as an important
modulator of TCR-mediated signaling that regulates T-cell activation, homeostasis and tolerance.
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Introduction
Transmembrane adaptor proteins (TRAPs) are a group of
molecules involved in immune cell activation [1]. Among these,
LAT, PAG/Cbp, NTAL/LAB and LIME are mainly localized in
the lipid rafts; while TRIM, SIT and LAX are excluded from the
raft fraction of the plasma membrane (reviewed in 1).
The common characteristic of TRAPs is the presence of several
tyrosine-based signaling motifs (TBSMs) within their cytoplasmic
tails. These are phosphorylated by protein tyrosine kinases of the
Src and Syk families, thereby, enabling the TRAPs to recruit SH2-
containing cytoplasmic signaling and/or effector proteins to the
plasma membrane. Thus, TRAPs function as important regulators
of signal transduction, connecting signal transducing cell-surface
receptors with downstream cellular signaling pathways [1].
During the last years, several groups have generated knockout
mice to investigate the in vivo function of these molecules. The data
demonstrate that TRAPs play an important role in the regulation
of immune-cell homeostasis. For example, LAT-deficient mice
display a severe alteration of the immune system and T-cell
development is completely blocked at the DN3 stage [2]. NTAL-
deficient mice develop a spontaneous autoimmune disease
characterized by splenomegaly, elevated levels of anti-double-
stranded DNA autoantibodies, and deposition of immune
complexes within the glomeruli [3]. Moreover, LAX-deficient
mice display hyperactive T, B and mast cells [4,5].
We have shown that SIT-deficient mice have altered thymic
selection and decreased numbers of peripheral naı ¨ve T cells [6–8].
Moreover, T cells from SIT
2/2 mice also display hyperresponsiveness
to CD3 stimulation and undergo enhanced lymphopenia-induced
expansion [6,7]. Finally, we showed that the clinical course of experi-
mental autoimmune encephalomyelitis (EAE) is more severe in
SIT
2/2 mice [6]. Thus, these data suggest that SIT plays an im-
portant role in T-cell homeostasis and in the establishment of tolerance.
In the present study, we extended our previous investigations on
the function of SIT. We focused particularly on how SIT regulates
signaling in T cells. We provide further evidence that SIT
negatively regulates proximal TCR signaling and TCR-mediated
phosphorylation of Akt in vitro. We additionally show that the
phosphorylation/inactivation of Foxo1, a transcription factor
downstream of Akt that inhibits cell cycle progression and
regulates T-cell homeostasis [9,10], is significantly enhanced in
SIT
2/2 T cells. Moreover, CD4
+ T cells within the secondary
lymphoid organs of SIT
2/2 mice show signs of mild hyperactiva-
tion. In summary, our studies demonstrate that SIT is an
important inhibitory molecule of T-cell activation.
Methods
Human Ethics
Approval for these studies involving the analysis of TCR-
mediated signaling in human T cells was obtained from the Ethics
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University, Magdeburg, Germany with the permission number
[107/09]. Informed consent was obtained in writing in accordance
with the Declaration of Helsinki.
Animal Ethics
All experiments were performed with samples taken from
euthanized animals in accordance with the German National
Guidelines for the Use of Experimental Animals (Animal
Protection Act, Tierschutzgesetz, TierSchG). Animals were
handled in accordance with the European Communities Council
Directive 86/609/EEC. All possible efforts were made to
minimize animal suffering and the number of animals used.
Mice
SIT
2/2 mice were previously described [6]. The mice were
maintained in a pathogen free condition.
Flow cytometry
Single cell suspensions were prepared from spleen. Subsequent-
ly, 1610
6 cells were stained with different monoclonal antibodies
for 15 min at 4uC, washed and then analyzed on a FACSCalibur
using the CellQuest software (Becton Dickinson). Antibodies were
purchased from BD Pharmingen. Anti-CD40L (MR1) Abs was
from eBioscience.
The analysis of Annexin V, Bcl-2, and BrdU was performed as
previously described [7].
Cell culture
Peripheral blood mononuclear cells were isolated by Ficoll
gradient (Biochrom) centrifugation of heparinized blood collected
from healthy volunteers. Human T cells were further purified by
non-T cell depletion using the Pan T cell isolation kit II (Miltenyi
Biotec). The purity of T cells, determined by flow cytometry, was
usually more then 96%. Cells were maintained in RPMI 1640
medium containing 10% FBS, stable L-glutamine, and 1000 U/
ml penicillin/streptomycin at 37uC with 5% CO2 over night
before transfection. Jurkat T cells (ATCC) were maintained in
RPMI 1640 medium supplemented with 10% FBS (PAN) and
stable L-glutamine at 37uC with 5% CO2.
RNA interference, plasmids and cell transfection
The following SIT siRNA duplex containing 25 nucleotides
were purchased from Invitrogen: 59-GGC UGC AGA GGA GGU
GAU GUG CUA U-39,5 9-GGG CUG UGA CGC UGC UAU
UUC UCA U-39 and 59-GCC AGA CCA GCA GGA UCC AAC
UCU U-39. As negative control we used a Renilla Luciferase
siRNA duplex from Invitrogen. To achieve efficient SIT
downregulation, primary human T cells (3610
6) were transfected
with a mix of siRNA (120 nM for each duplex) using the
Nucleofection Kit (Amaxa) according to the manufacturer’s
instruction or the Gene Pulser Xcell (Bio-Rad) as previously
described [11]. Cells were harvested 72 h after electroporation.
20610
6 Jurkat T cells were resuspended in 0.4 ml of PBS
containing Ca
2+ and Mg
2+ and incubated with a mix of siRNA
(200 nM for each duplex). Cells were transfected using Gene
Pulser II (Bio-Rad) set at 230 mV, 950 mF. Cells were cultured for
48 h after electroporation.
Cell stimulation, Immunoblotting, and
immunoprecipitation
Purified mouse CD4
+ T cells were stimulated at 37uC with
5 mg/ml soluble anti-mouse CD3e (145-2C11; BD Biosciences)
without cross-linking for the indicated time points. Human T cells
were stimulated at 37uC by using OKT3 mAb without cross-
linking for the indicated time points. Cell lysates were prepared
and analyzed as previously described [12]. Anti-pS
473Akt (PKB),
anti-pY
319ZAP70, anti-pY
191LAT, anti-pS
256Foxo1, (all from Cell
Signaling Technology), anti-pY
783PLCc-1, CD3e (Santa Cruz
Biotechnology), anti-pY
145SLP-76 (BD Biosciences), anti-b-actin
(clone AC-15) (Sigma-Aldrich), anti-p-Tyr (4G10) (Upstate
Biotechnology), anti-ZAP-70 (Transduction Laboratories), and
anti-SIT [13] antibodies were used for Western blotting. The
intensity of the detected bands was acquired using the Kodak
Image station 2000R and analysis was performed using ID Image
software (Kodak).
In immunoprecipitation experiments, 10610
6 Jurkat T cells
were either left unstimulated or stimulated with 5 mg/ml purified
OKT3 mAb without cross-linking for 5 min at 37uC. Cell lysates
were immunoprecipitated with agarose-conjugated CD3f (Santa
Cruz Biotechnology) (Santa Cruz Biotechnology) antibody fol-
lowed by recombinant protein G-Sepharose 4B (Zymed Labora-
tories Inc.) at 4uC overnight. After washing, CD3f immunopre-
cipitates were resolved by SDS-PAGE, transferred to a membrane,
and analyzed by immunoblotting with the indicated antibodies.
Statistics
Statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA). p values were
determined by an unpaired two-tailed Student’s t test.
Results
Loss of SIT results in an enhanced activation of the TCR-
mediated Akt-Foxo pathway
Recently, we have shown that SIT is an important modulator of
T-lymphocyte functions. SIT negatively regulates selection
processes within the thymus, peripheral T-cell activation and T-
cell homeostasis [6–8]. Moreover, SIT-deficient mice are more
susceptible to the development of EAE, a mouse model of Multiple
Sclerosis [6]. As the data suggest that SIT plays an inhibitory role
in T cells, we have next attempted to investigate whether SIT
influences TCR-mediated signaling. However, we have found that
SIT-deficient T cells develop sensory adaptation and are
refractory to stimulation upon extensive crosslinking of the
TCR/CD3 complex [7], Therefore, we used an alternative
stimulation condition that induces only a minimal crosslinking of
the antigen receptor on T cells, thus better mimicking the
physiological situation. Under these conditions of stimulation, we
found that SIT-deficient T cells show enhanced Akt phosphory-
lation (figure 1). We next investigated which intracellular signaling
pathways might be affected by the augmented Akt activation in
SIT-deficient T cells. We have shown that the loss of SIT results in
an enhanced T-cell proliferation [6,7]. Therefore, as a putative
target of Akt, we chose Foxo1, a member of the Forkhead family of
transcription factors, which is implicated in cell cycle regulation
[9]. One of the known functions of Foxo is to activate the
transcription of the cell cycle inhibitor p27
kip1. Members of the
Foxo family are phosphorylated by Akt. Phosphorylation by Akt
results in the sequestration of Foxo1 into the cytosol, thus
preventing p27
kip1 transcription and cell cycle inhibition. Although
well characterized in other cellular systems, it is poorly understood
how the Akt-Foxo pathway is activated in T cells. Recently, it has
been shown in T cells that Vav1 activates the PI3K-Akt-Foxo1
pathway, thus regulating cell cycle progression [14]. Loss of Vav1
resulted in reduced activation of Akt, blunted Foxo1 phosphor-
ylation, and cell cycle arrest. Conversely to Vav1
2/2 T cells, SIT-
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activation. Thus, we expected to observe an enhanced phosphory-
lation of Foxo1 in SIT
2/2 T cells. As shown in figure 1, we found
that the level of phospho-Foxo1 is indeed higher in lysates from SIT-
deficient CD4
+ T cells than in wild type cells. These results suggest
that SIT inhibits TCR-mediated Akt activation and Foxo1
phosphorylation, thus likely negatively regulating T-cell proliferation.
Suppression of SIT expression enhanced proximal TCR
signaling
As mentioned above, SIT-deficient mouse T cells develop
compensatory mechanisms that alter proximal TCR signaling [7].
Therefore, the enhanced phosphorylation of Akt observed in SIT-
deficient T cells could be due to the altered status of SIT-deficient
mouse T cells. To confirm that SIT regulates Akt activation, we
Figure 1. Enhanced phosphorylation of Akt and Foxo1 in SIT
2/2 CD4
+ T cells. Purified splenic CD4
+ T cells from 3–4 month-old SIT
2/2 or
WT mice were stimulated with non-crosslinked CD3 (clone 145-2C11) mAb for the indicated times. Samples were analyzed by Western blotting using
the indicated Abs. The phosphorylated Akt and Foxo1 bands were quantified using the ImageQuant software and values were normalized to the
corresponding b-actin signal. Graphs show the phosphorylation levels of Akt and Foxo1 shown as of arbitrary units 6 SEM of at least 3 independent
experiments. Statistical significance * p,0.05.
doi:10.1371/journal.pone.0023761.g001
Figure 2. Downregulation of SIT results in an enhanced TCR-mediated signaling in primary human T cells. A) Primary human T cells
were transfected with control or SIT-specific siRNA and 72 h later were stimulated with non-crosslinked CD3 (clone OKT3) mAb for the indicated
times. Cell lysates were analyzed by immunoblotting using phosphospecific antibodies for ZAP-70, PLCc-1, and Akt. Immunoblots verifying SIT
downregulation are shown. B) Phosphorylated bands were quantified using the ImageQuant software and values were normalized to the
corresponding b-actin signal. Graphs show the phosphorylation levels of ZAP-70, PLCc-1, and Akt shown as of arbitrary units 6 SEM of 2, 4, and 6
independent experiments, respectively. Statistical significance in B) * p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0023761.g002
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results shown in figure 2 demonstrate that, similar to mouse T
cells, downregulation of SIT in human primary T cells results in
an enhanced TCR-mediated Akt phosphorylation.
Collectively, these data suggest that SIT regulates T-cell
activation likely by inhibiting proximal TCR signaling events
leading to Akt activation. Therefore, we next analyzed proximal
TCR signaling in primary human T cells upon downregulation of
Figure 3. Suppression of SIT expression results in an enhanced proximal TCR signaling. siRNA duplex for SIT or control were introduced
in Jurkat T cells by electroporation. Cells were stimulated 48 h after transfection with non-cross-linked CD3 Ab for the indicated times. Total cell
lysates (A–B) or TCRf immunoprecipitates (C) were prepared and analyzed by Western blotting using the indicated Abs. The data are representative
of at least 3 independent experiments. Immunoblots verifying SIT downregulation are shown. Equal loading is shown by reprobing immunoblots
with antibodies specific for b-actin (A–B) or TCRf (C). The phosphorylated bands were quantified using ImageQuant software and values were
normalized to the corresponding b-actin signal. Graphs show the phosphorylation levels shown as of arbitrary units 6 SEM of at least 3 independent
experiments. Statistical significance * p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0023761.g003
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both ZAP-70 and PLCc-1 was enhanced. Thus, it appears that
SIT suppresses proximal TCR signaling.
In primary human T cells, the downregulation efficiency of SIT
is approximately 50% (figure 2A). In order to obtain a more
efficient suppression of SIT, we used the Jurkat T-cell line. As
shown in figure 3, we were able to downregulate up to 70–90% of
SIT in Jurkat T cells. Therefore, we used this well-characterized
T-cell line to further analyze the role of SIT on proximal TCR
signaling. The data presented in figure 3A show that, similar to the
downregulation of SIT in primary human T cells, also suppression
of SIT in Jurkat T cells results in an enhanced proximal TCR
signaling. SIT-depleted Jurkat T cells showed an augmented
TCR-mediated phosphorylation of ZAP-70, LAT, SLP-76 and
PLCc-1 (figure 3A). We additionally found that suppression of SIT
strongly enhanced Akt phosphorylation upon CD3 stimulation
even in a system where Akt is already constitutively activated
(figure 3B) [15,16].
To further elucidate the mechanism responsible for the
enhanced proximal TCR signaling, we investigated TCRf
phosphorylation and TCRf/ZAP-70 association. In agreement
with the enhanced phosphorylation of ZAP-70, LAT, SLP-76, and
PLCc-1, the phosphorylation of TCRf was also enhanced upon
suppression of SIT expression (figure 3C). Additionally, analysis of
Figure 4. Analysis of activation markers in SIT
2/2 mice. A) Splenic CD4
+ T cells from 1 year-old SIT-deficient and wild-type mice were analyzed
for CD69 expression. Numbers within histograms indicate the percentage of cells. One representative profile per group is shown. B) Comparison of
CD40L expression on CD4
+ T cells isolated from SIT-deficient (empty histogram) and wild-type (filled histogram) mice. Mean fluorescent intensity
(MFI) from one representative mouse per group is indicated. C) Comparison of CD5 expression on CD4
+ T cells isolated from SIT-deficient (empty
histogram) and wild-type (filled histogram) mice. Bar graphs in A), B), and C) represent statistical analyses of CD69, CD40L, and CD5 expression,
respectively. Data derive from at least 5 mice per group. Statistical significance * p,0.05 and ***p,0.0001.
doi:10.1371/journal.pone.0023761.g004
Table 1. T-cell subsets in lymph nodes.
Genotype bTCR
+CD45RB
+ bTCR
+CD62L
+ CD4
+CD25
+ CD4
+CD103
+
SIT
+/+ 32.863.5 (n=6) 66.367.0 (n=4) 7.560.2 (n=3) 2.860.5 (n=10)
SIT
2/2 27.261.8 (n=6) 60.367.5 (n=4) 7.660.6 (n=3) 2.860.4 (n=10)
% of lymph node cells 6 SEM. n=number of examined mice.
doi:10.1371/journal.pone.0023761.t001
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70 was also increased in SIT dim T cells (figure 3C). Thus, these
data suggest that suppression of SIT expression enhanced
proximal TCR signaling at the level of TCRf phosphorylation.
Increased proportion of activated CD4
+ T cells in aged
SIT-deficient mice
The PI3K-Akt pathway regulates a variety of cellular processes
including proliferation and apoptosis. Therefore, we next
investigated whether SIT
2/2 mice developed any dysfunction
within the lymphocyte compartment. We found that CD4
+ T cells
from aged SIT
2/2 mice showed a modest but consistent increase
in the expression of CD69 and CD40L (figure 4A, 4B). Moreover,
these cells also express increased levels of CD5 (figure 4C), which
we have previously shown to be altered also in thymocytes and
CD8
+ T cells [6,7]. We additionally analyzed the expression of a
variety of other surface markers, including CD3, CD4, CD25,
CD44, CD45RB, CD62L, and CD103, but we did not observe
significant differences between WT and SIT-deficient mice ([6,7],
table 1, and table 2). We also did not observe significant
differences in the size of secondary lymphoid organs. In fact, the
numbers of total splenocytes, total splenic CD4
+ T cells, and
effector/memory CD4
+ T cells in the spleen were not affected
(table 2). We found only a modest decrease in the number of CD4
+
T cells in lymph nodes [6]. Finally, we also did not observe
significant differences in BrdU incorporation (figure 5A), in the
intracellular expression of the antiapoptotic molecules Bcl-2
(figure 5B), and in Annexin V expression (figure 5C) on ex vivo
isolated CD4
+ T cells from SIT-deficient mice. Thus, these data
indicate that loss of SIT results in a partial alteration of the
activation status of CD4
+ T cells without affecting their steady-
state proliferation or apoptosis. We hypothesize that the
compensatory mechanism displayed by SIT-deficient mice may
prevent the development of a more severe hyperactivation of T
cells and lymphoproliferative diseases.
Discussion
In this study, we provide new insights into the function of the
transmembrane adaptor protein SIT. We show that SIT inhibits
TCR-mediated signaling. This is an important finding as the
mechanism by which SIT inhibits T-cell activation was not clear.
We have previously shown that overexpression of SIT suppressed
transcription of an NFAT-driven reporter gene in the Jurkat T-cell
line [13]. However, we did not find obvious alterations of more
proximal TCR signaling events in this T-cell line upon strong
stimulation of the antigen receptor. Here, we now show that SIT
negatively regulates the phosphorylation/activation of crucial
signaling molecules such as ZAP-70, LAT, PLCc-1, and Akt
upon weak T-cell stimulation. Potential clues to the mechanisms
underlying the inhibitory effect of SIT on TCR-mediated signaling
may be provided by recent unexpected observations suggesting
that Grb2 amplifies TCR signaling by regulating Lck activation
[17]. SIT possesses two Grb2 consensus binding motifs and indeed
inducibly binds Grb2 upon TCR stimulation [13,18]. It has been
suggested that non-raft TRAPs inhibit antigen-receptor-mediated
signaling by sequestering signaling molecules away from the lipid
rafts [1]. Thus, we propose a scenario whereby SIT, by
functioning as a dosage regulator of Grb2 at the plasma
membrane, may in turn dampen proximal TCR signaling.
We have additionally uncovered a link between the transmem-
brane adaptor SIT and the Akt-Foxo1 pathway. Whether SIT
inhibits the phosphorylation of Akt-Foxo1 directly or indirectly
(i.e. by negatively regulating proximal signaling) requires further
investigation. Nevertheless, our study adds new insights into the
regulation of Foxo1 in T cells. We show that low affinity ligands
induced Foxo1 phosphorylation/inactivation in mouse T cells and
that the loss of SIT enhances the TCR-mediated inactivation of
Foxo1. Thus, SIT could modulate cell cycle progression (e.g.
triggered by low affinity ligands) via Foxo1. Intriguingly, similar to
SIT
2/2 mice [6,7] Foxo1
2/2 mice display reduced numbers of
naı ¨ve cells and an accumulation of CD44
hi memory-like T cells
[10]. It will be interesting to determine whether SIT is involved in
the regulation of other members of the Foxo family such as Foxo4
and Foxo3a. In fact, the characterization of Foxo3a-deficient mice
revealed a phenotype resembling that of SIT-deficient mice, such
as T-cell hyperactivation, enhanced production of IL-2 and Th1
and Th2 cytokines [19].
We have previously shown that SIT regulates thymocyte
selection [6,8]. It is tempting to speculate that an altered Foxo-
mediated pathway also accounts for the defects in thymic
development in SIT-deficient mice. Indeed, it has been recently
Figure 5. Normal survival and steady-state proliferation of SIT-deficient CD4
+ T cells. Lymph node cells were isolated and stained with
CD4 and CD8 mAbs. A) BrdU incorporation was measured for CD4
+ T cells. Bar graphs indicate mean values 6 SEM from 3 SIT
2/
2 and 5 SIT
+/
+ mice. B)
Intracellular Bcl-2 expression in CD4
+ T cells from SIT
2/
2 (empty histogram) and SIT
+/
+ (filled histogram) mice. Isotype control is shown as a gray line.
C) Annexin V expression on CD4
+ T cells. Bar graphs indicate mean values 6 SEM from 3 SIT
2/
2 and 3 SIT
+/
+ mice.
doi:10.1371/journal.pone.0023761.g005
Table 2. T-cell subpopulations in the spleen.
Genotype Splenocytes CD4
+ CD4
+CD44
hiCD62
lo
SIT
+/+ (n=8) 111.3624.6 19.666.5 8.6463.8
SIT
2/2 (n=8) 98.8626.1 19.664.1 11.4462.5
Number of cells in the spleen (610
6) 6 SEM. n=number of examined mice.
doi:10.1371/journal.pone.0023761.t002
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ment via Akt-Foxo3a [20]. How Foxo family members regulate
lymphocyte development is not yet clear. They may be involved in
the regulation of transcriptional activation of genes required in
developmental processes.
Our data suggest that the loss of SIT also results in an altered
function of CD4
+ T cells. In fact, both TCR-mediated signaling
and the expression levels of CD69 and CD40L are augmented.
Moreover, we have previously shown that SIT-deficient T cells
were hyperresponsive to CD3 stimulation, produced higher
amount of cytokines in vitro, and more importantly, displayed a
more severe clinical course of the experimentally induced
autoimmunity EAE [6]. Thus, it appears that the loss of SIT
generally enhances the activation status of T lymphocytes. Despite
the fact that T cells are hyperactivated, SIT-deficient mice do not
develop signs of chronic inflammation or lymphoproliferation. We
propose that the development of compensatory mechanisms in
SIT-deficient mice [7] could serve to prevent autoimmunity or
chronic inflammatory processes, thus preserving immune func-
tions. However, whether sensory adaptation is completely effective
is currently under investigations. In fact, we have recently found
that SIT-deficient mice spontaneously develop anti-nuclear
antibodies and glomerulonephritis (Arndt and Simeoni, unpub-
lished observations).
In summary, the data presented here together with previous
studies demonstrate a critical function for SIT in fine-tuning
signals emanating from the TCR leading to proliferation,
differentiation and tolerance and further emphasize the important
role that TRAPs play in regulating homeostasis within the immune
system.
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